Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.

Blaheta, Roman A. and Michaelis, Martin and Driever, Pablo Hernáiz and Cinatl, Jindrich (2005) Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Medicinal Research Reviews, 25 (4). pp. 383-97. ISSN 0198-6325. (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. (Contact us about this Publication)

Abstract

The short chain fatty acid valproic acid (VPA) and VPA-analogs modulate the biology of diverse tumor cell entities by inducing differentiation, inhibiting proliferation, increasing apoptosis, and immunogenicity and by decreasing metastatic and angiogenetic potential. This review updates an earlier one in 2002, reflecting the interest in VPA as a potent anticancer drug. A number of in vitro studies show that the types of known tumor cells susceptible to VPA is steadily increasing. Of special note is the strong antineoplastic activity of VPA in chemoresistant cancer cells. A novel and promising approach is combining VPA with other drugs to achieve a broad therapeutic index. Clinical studies are underway and the preliminary results indicate that VPA alone or in combination offers a promising avenue of treatment, both in solid and hematopoetic malignancies.

Item Type: Article
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculties > Sciences > School of Biosciences
Depositing User: Martin Michaelis
Date Deposited: 05 Jun 2013 20:29 UTC
Last Modified: 17 Jun 2014 13:44 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/34113 (The current URI for this page, for reference purposes)
  • Depositors only (login required):